FDA Approves Groundbreaking Hep B Treatment

A new era in treating chronic hepatitis B (CHB) has begun with the FDA's approval of bepirovirsen, marketed as Hibsago. This groundbreaking medication represents a potential functional cure for the liver condition that affects millions globally and is responsible for over a million deaths annually. Results from two Phase 3 clinical trials, published in the New England Journal of Medicine, revealed that a six-month course of bepirovirsen injections achieved a functional cure in 19% of participants.

Bepirovirsen suppresses the hepatitis B virus to undetectable levels, a significant departure from current treatments that only manage the infection. In patients who responded to the drug, the infection remained under control for at least 24 weeks after treatment stopped. This treatment advancement offers the possibility for patients to stop long-term antiviral medication. However, some serious side effects, including liver inflammation, were noted, necessitating regular blood monitoring.

This approval is a major step forward, particularly for the United States, providing a new treatment approach that could lead to sustained viral control post-treatment. The effectiveness of bepirovirsen appears to be influenced by initial viral protein levels, suggesting potential pre-treatment testing. Researchers are exploring combinations with other drugs to enhance efficacy, with aspirations for broader global accessibility.